Actively Recruiting

Age: 18Years +
All Genders
NCT05857800

Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment

Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2023-06-08

2000

Participants Needed

1

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This translational study aims to investigate how neoadjuvant therapy affects lung cancer patients by monitoring dynamic changes in the tumor environment. The study focuses on patients with histologically confirmed lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), who are eligible for neoadjuvant therapy in the LungMate clinical trial series. By analyzing intra-tumour genetic and functional heterogeneity following neoadjuvant therapy through multi-omic analysis (including genomics, transcriptomics, metabolomics and proteomics), this study could potentially identify new biomarkers or therapeutic targets that could improve lung cancer patient outcomes.

CONDITIONS

Official Title

Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients enrolled in LungMate clinical trial series, including LungMate-001 through LungMate-015 and future LungMate neoadjuvant therapy lung cancer trials
  • Age 18 years or older
  • Histologically confirmed diagnosis of non-small cell lung cancer or small cell lung cancer
  • Written informed consent provided
Not Eligible

You will not qualify if you...

  • Patients who do not meet clinical trial screening criteria or who dropped out of the clinical trial
  • Any condition that makes participation undesirable or risks protocol compliance, as judged by the investigator
  • History of other cancers within 5 years before the trial, except cervical carcinoma in situ, cured basal cell carcinoma, and bladder epithelial tumors (including Ta and Tis)
  • Carrier of active hepatitis B, hepatitis C, or HIV infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Shanghai Pulmonary Hospital

Shanghai, China, 200433

Actively Recruiting

Loading map...

Research Team

P

Peng Zhang, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here